JP2009519949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519949A5 JP2009519949A5 JP2008545850A JP2008545850A JP2009519949A5 JP 2009519949 A5 JP2009519949 A5 JP 2009519949A5 JP 2008545850 A JP2008545850 A JP 2008545850A JP 2008545850 A JP2008545850 A JP 2008545850A JP 2009519949 A5 JP2009519949 A5 JP 2009519949A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- des
- peptide
- octapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75141205P | 2005-12-16 | 2005-12-16 | |
| PCT/US2006/047953 WO2007075439A2 (en) | 2005-12-16 | 2006-12-15 | Compositions and methods for treating obesity and related metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519949A JP2009519949A (ja) | 2009-05-21 |
| JP2009519949A5 true JP2009519949A5 (cg-RX-API-DMAC10.html) | 2010-01-21 |
Family
ID=38218466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545850A Pending JP2009519949A (ja) | 2005-12-16 | 2006-12-15 | 肥満症および関連する代謝性疾患の治療のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090209460A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1973953A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2009519949A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006329836A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2634016A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007075439A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| EP2020990B1 (en) | 2006-05-30 | 2010-09-22 | Intarcia Therapeutics, Inc | Two-piece, internal-channel osmotic delivery system flow modulator |
| PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
| EP2120985B1 (en) | 2007-02-05 | 2012-06-27 | Amylin Pharmaceuticals, Inc. | FN-38 peptides for use in the treatment of psychotic and anxiety disorders |
| EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
| KR20100059863A (ko) * | 2007-09-11 | 2010-06-04 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도 |
| US20100204107A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of urodilatin as a therapeutic agent |
| EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
| ES2525179T3 (es) | 2009-04-08 | 2014-12-18 | Takeda Pharmaceutical Company Limited | Derivado de neuromedina U |
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| JP2013209295A (ja) | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| ES2968262T3 (es) | 2015-06-03 | 2024-05-08 | I2O Therapeutics Inc | Sistemas de colocación de implantes |
| KR20240037175A (ko) | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| US12161694B2 (en) | 2017-03-24 | 2024-12-10 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| US20240279278A1 (en) | 2023-01-12 | 2024-08-22 | Boehringer Ingelheim International Gmbh | Nmu receptor 2 agonists |
| WO2026013210A1 (en) | 2024-07-11 | 2026-01-15 | Boehringer Ingelheim International Gmbh | Novel nmu receptor 2 agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081418A1 (en) * | 2000-04-27 | 2001-11-01 | Merck & Co., Inc. | New neuromedin u receptor nmur2 and nucleotides encoding it |
| JP2002265497A (ja) * | 2001-03-12 | 2002-09-18 | Tadashi Hashimoto | 生理活性ペプチドニューロメジンｕの高活性誘導体 |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| US7943580B2 (en) * | 2004-12-24 | 2011-05-17 | National Cerebral And Cardiovascular Center | Polypeptide and the use thereof |
| EP1922336B1 (en) * | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| EP2120985B1 (en) * | 2007-02-05 | 2012-06-27 | Amylin Pharmaceuticals, Inc. | FN-38 peptides for use in the treatment of psychotic and anxiety disorders |
-
2006
- 2006-12-15 AU AU2006329836A patent/AU2006329836A1/en not_active Abandoned
- 2006-12-15 WO PCT/US2006/047953 patent/WO2007075439A2/en not_active Ceased
- 2006-12-15 JP JP2008545850A patent/JP2009519949A/ja active Pending
- 2006-12-15 EP EP06845564A patent/EP1973953A2/en not_active Withdrawn
- 2006-12-15 CA CA002634016A patent/CA2634016A1/en not_active Abandoned
- 2006-12-15 US US12/097,737 patent/US20090209460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201322B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| ES2976562T3 (es) | Derivado del glucagón | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2006515351A5 (cg-RX-API-DMAC10.html) | ||
| BR112013032375B1 (pt) | Conjugado, composição farmacêutica e uso dos mesmos | |
| US12018060B2 (en) | Glucagon derivatives | |
| TW201202265A (en) | Glucagon analogues | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| US20090209460A1 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
| BR112020003319A2 (pt) | análogo de peptídeo de oxintomodulina acilada | |
| KR20260025094A (ko) | 개선된 특성을 가진 유사체 | |
| WO2024261076A1 (en) | Weight loss | |
| HK40010066B (en) | Glucagon derivative | |
| NZ727090A (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| HK1192261B (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ731342B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| BR112017014205B1 (pt) | Derivados de glucagon e seu uso, e uso de uma composição farmacêutica | |
| NZ717174B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ740049B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ734808B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |